National and Kapodistrian University of Athens
Ανίχνευση μεταλλαγμένων στελεχών του HBV κατά τη θεραπεία με νουκλεοσιδικά ανάλογα ασθενών με χρόνια ηπατίτιδα Β
Abstract
dc:descriptionIn this study included 125 treatment-naïve patients with HBeAg negative chronic hepatitis B who started long-term monotherapy with lamivudine 100 mg daily (78 patients, 58 with compensated and 20 with decompensated liver disease) or adefovir 10mg daily (47 patients with decompensated disease), and 42 patients with HBeAg negative chronic hepatitis B and resistance to lamivudine (all with compensated disease) who received either a combination of lamivudine and adefovir (28 patients) or monotherapy adefovir (14 patients). Of the patients who started treatment with lamivudine, viral breakthrough was observed in 45 of 78 (58%) patients from 6 months to 9 years after the start of administration of lamivudine. Analyzing separately the subgroup of 39 patients who completed the ten-year follow-up found that viral breakthrough was observed in 30 of them (77%). Genome analysis to detect mutations conducted in 34 patients. 9 patients had the mutation M204I (27%), 14 had the combination M204I + L180M (41%), and the remaining 11 had the combined mutations M204V + L180M (32%). After viral breakthrough, all patients with initial virological and biochemical response showed biochemical breakthrough in a period of two years. Patients who had biochemical breakthrough in the first 6 months after virological rebound had significantly higher HBV DNA levels than those who did not have this rapid (within 6 months) biochemical rebound (median HBV DNA 20272 vs. 1813 copies/ml, P=0.01). Of the patients who started adefovir, mutants resistant to adefovir observed in 7 patients (15%). One patient experienced viral escape in the first year of treatment, 2 patients in the second year and the remaining 3 in the third year of treatment. Four patients had the N236T mutation and the other three had the A181V mutation. Of the 15 patients who had no complete virological response at 12 months, 3 of them developed resistance (20%), while of the 32 patients who achieved a complete virological response at 12 months, resistance developed by the four of them (12%). Of the 4 patients with initial complete virologival and biochemical response, biochemical breakthrough was observed in 2 of them. Of the patients with resistance to lamivudine, receiving adefovir monotherapy or combination adefovir and lamivudine therapy, mutants to adefovir found only in the monotherapy group (in the 3 patients who did not achieve a complete virologic response). The appearance of resistance found at 15, 18, and 18 months respectively with selection of the N236T mutant in the first patient, the A181V in the second patient and mixed population of N236T and A181V in the third. Genotyping resistance followed virological and biochemical breakthrough was observed in 2 patients and only virological rebound in the third (with mixed population). The final outcome of patients studied in the largest group of those who started antiviral treatment with lamivudine and not lost to follow-up (55 out of 78 patients). All patients who developed viral escape due to emergence of resistance in lamivudine recieved second-line antiviral therapy depending on the availability of antivirals in the corresponding period of monitoring. 14 patients died and 2 underwent liver transplantation. Eight of the patients developed hepatocellular cancer (14%, 8/55) and ten patients lost HBsAg (18%, 10/55).In conclusion, the nucleos(t)ides lamivudine and adefovir are related with emergence and predominance of mutant strains resistant to the action of drugs resulting in the breakthrough of viral replication. The development of resistance is more common in the first year of treatment but the possibility is not eliminated even after almost ten years of administration of the drugs. Adding on another anti-virus that does not show cross-resistance and not switch to, it seems the best choice among the antivirals lamivudine and adefovir as this strategy eliminates the risk of recurrence of viral escape mutants because of emergence new resistant strains.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadimitropoulos, Vasileios
- Παπαδημητρόπουλος, Βασίλειος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40214